KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials (2017 - 2021)

Historic Raw Materials for Aquestive Therapeutics (AQST) over the last 5 years, with Q1 2021 value amounting to $833000.0.

  • Aquestive Therapeutics' Raw Materials fell 3517.51% to $833000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $833000.0, marking a year-over-year decrease of 3517.51%. This contributed to the annual value of $789000.0 for FY2020, which is 3657.56% down from last year.
  • As of Q1 2021, Aquestive Therapeutics' Raw Materials stood at $833000.0, which was down 3517.51% from $789000.0 recorded in Q4 2020.
  • Aquestive Therapeutics' 5-year Raw Materials high stood at $1.4 million for Q1 2019, and its period low was $725000.0 during Q4 2017.
  • Its 5-year average for Raw Materials is $1.1 million, with a median of $1.2 million in 2020.
  • As far as peak fluctuations go, Aquestive Therapeutics' Raw Materials soared by 7696.55% in 2018, and later crashed by 3657.56% in 2020.
  • Over the past 5 years, Aquestive Therapeutics' Raw Materials (Quarter) stood at $725000.0 in 2017, then soared by 76.97% to $1.3 million in 2018, then decreased by 3.04% to $1.2 million in 2019, then crashed by 36.58% to $789000.0 in 2020, then increased by 5.58% to $833000.0 in 2021.
  • Its last three reported values are $833000.0 in Q1 2021, $789000.0 for Q4 2020, and $1.2 million during Q3 2020.